Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized And Multicentric Phase III Study Evaluating The Benefit By Using A Chemotherapy With FEC 100 And Docetaxel In Non Metastatic Breast Cancer Which Has Relapsed After A Conservative Surgery

NCT00053911 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT00053911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00053911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized And Multicentric Phase III Study Evaluating The Benefit By Using A Chemotherapy With FEC 100 And Docetaxel In Non Metastatic Breast Cancer Which Has Relapsed After A Conservative Surgery
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2002
Completion date
Not reported
Enrollment
Not reported
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer